These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23738723)

  • 1. Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure.
    White MP; Babayeva M; Taft DR; Maniar M
    J Pharm Pharmacol; 2013 Jul; 65(7):960-9. PubMed ID: 23738723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
    Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
    Komrokji RS; Raza A; Lancet JE; Ren C; Taft D; Maniar M; Wilhelm F; List AF
    Br J Haematol; 2013 Aug; 162(4):517-24. PubMed ID: 23789936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
    Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
    Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients with advanced cancer.
    Advani SH; Achrekar SD; Doval DC; Raghunadharao D; Wilhelm FE; Acharya M
    Indian J Cancer; 2014; 51(1):40-4. PubMed ID: 24947095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.
    Zhang Y; Hsieh Y; Izumi T; Lin ET; Benet LZ
    J Pharmacol Exp Ther; 1998 Oct; 287(1):246-52. PubMed ID: 9765344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein.
    Ye L; Wang T; Tang L; Liu W; Yang Z; Zhou J; Zheng Z; Cai Z; Hu M; Liu Z
    J Pharm Sci; 2011 Nov; 100(11):5007-17. PubMed ID: 21721007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine.
    Xia B; Liu X; Zhou Q; Feng Q; Li Y; Liu W; Liu Z
    Drug Dev Ind Pharm; 2013 Jun; 39(6):845-53. PubMed ID: 22563974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
    Dahan A; Amidon GL
    Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase: comparative studies using in vitro, in situ and in vivo models.
    Sun H; Bi H; Huang M; Liu D; Qin Z
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):486-94. PubMed ID: 20936649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
    Collett A; Higgs NB; Sims E; Rowland M; Warhurst G
    J Pharmacol Exp Ther; 1999 Jan; 288(1):171-8. PubMed ID: 9862768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
    Chun AW; Cosenza SC; Taft DR; Maniar M
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of human absorption of a trioxane antimalarial drug (CDRI 99/411) using an in-house validated in situ single-pass intestinal perfusion model.
    Wahajuddin ; Singh SP; Patel K; Pradhan T; Siddiqui HH; Singh SK
    Arzneimittelforschung; 2011; 61(9):532-7. PubMed ID: 22029231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal permeability of forskolin by in situ single pass perfusion in rats.
    Liu ZJ; Jiang DB; Tian LL; Yin JJ; Huang JM; Weng WY
    Planta Med; 2012 May; 78(7):698-702. PubMed ID: 22411728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.
    Kang MJ; Kim HS; Jeon HS; Park JH; Lee BS; Ahn BK; Moon KY; Choi YW
    Drug Dev Ind Pharm; 2012 May; 38(5):587-96. PubMed ID: 21988221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked impact of P-glycoprotein on the absorption of TAK-427 in rats.
    Takeuchi T; Nonaka M; Yoshitomi S; Higuchi T; Ebihara T; Maeshiba Y; Kawase M; Asahi S
    Biopharm Drug Dispos; 2008 Sep; 29(6):311-23. PubMed ID: 18651556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral bioavailability and intestinal disposition of dehydroandrographolide in rats].
    Ye L; Liang F; Yang X; Shi J; Wang F; Liu W; Zhao J; Liu Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Aug; 32(8):1074-81. PubMed ID: 22931595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
    Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
    Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
    Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.